In a mutant p53 lung adenocarcinoma 129S2/SvPasCrl (129) mouse model, simultaneous delivery of AF and olaparib via oral gavage significantly reduced tumor growth compared to monotherapies. Here, TP53 is linked to lung adenocarcinoma.